Viatris Secures FDA Approvals for Four New Drugs, Advancing R&D Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: PRnewswire
- Regulatory Milestone: Viatris announced FDA approvals for four new drugs, including octreotide acetate for injectable suspension using microsphere technology, marking significant R&D advancements in 2025 and reinforcing the company's capabilities in navigating complex regulatory pathways.
- Injectable Expansion: This approval represents the company's fourth injectable FDA approval in 2025, demonstrating strategic success in expanding its high-value generics portfolio, which is expected to enhance market competitiveness.
- Contraceptive Patch Innovation: The low-dose estrogen weekly patch under development targets women suitable for combined hormonal contraception, with a planned 505(b)(2) NDA submission, highlighting the company's commitment to addressing unmet needs in women's health and filling market gaps.
- Neurotrophic Keratopathy Treatment: MR-146, utilizing a first-of-its-kind gene therapy platform for a rare corneal disease affecting approximately 73,000 patients in the U.S., plans to initiate clinical trials in the first half of 2026, showcasing the company's potential in innovative treatment areas.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 12.970
Low
10.00
Averages
13.25
High
16.00
Current: 12.970
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viatris (VTRS) Launches Inpefa in UAE, Plans Future Expansions Across Multiple Countries
- Drug Launch: Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this heart failure treatment within its territories and initiating its global expansion strategy.
- Clinical Trial Results: Inpefa demonstrated a 33% reduction in the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death in recently hospitalized patients, based on over 11,800 participants in two pivotal Phase 3 trials.
- Cardiovascular Risk Reduction: In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease, highlighting its significance in cardiovascular disease management.
- Market Reaction: Despite VTRS shares trading at $12.73, down 1.01% in pre-market activity, the drug's launch is expected to drive future revenue growth and enhance market share for the company.
Continue Reading
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
- Leadership Change: Viatris has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer, aiming to enhance company culture and global connectivity through integrated internal and external communication strategies, which will improve employee engagement and corporate image.
- Experienced Leader: With over 25 years of experience leading cross-functional teams, Ramsburg's previous roles at Viatris and its legacy company Mylan, particularly in corporate affairs, will help maintain strategic alignment during the company's transformation.
- Strategic Integration: In her new role, Ramsburg will oversee critical areas such as global talent, employee experience, and HR solutions, enhancing the company's strategic execution in employee welfare and development.
- Future Outlook: Viatris executive Andrew Enrietti stated that Ramsburg's appointment will support the company as it enters its next growth phase, emphasizing that employee engagement and well-being are the company's most important assets, which will continue to drive the achievement of strategic objectives.
Continue Reading